Climb Bio Statistics
Total Valuation
Climb Bio has a market cap or net worth of $689.59 million. The enterprise value is $463.03 million.
| Market Cap | 689.59M |
| Enterprise Value | 463.03M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Climb Bio has 58.74 million shares outstanding. The number of shares has increased by 6.58% in one year.
| Current Share Class | 58.74M |
| Shares Outstanding | 58.74M |
| Shares Change (YoY) | +6.58% |
| Shares Change (QoQ) | +5.09% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 83.30% |
| Float | 36.90M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.97 |
| P/TBV Ratio | 3.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.58, with a Debt / Equity ratio of 0.00.
| Current Ratio | 26.58 |
| Quick Ratio | 25.98 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.28% and return on invested capital (ROIC) is -20.52%.
| Return on Equity (ROE) | -29.28% |
| Return on Assets (ROA) | -19.92% |
| Return on Invested Capital (ROIC) | -20.52% |
| Return on Capital Employed (ROCE) | -29.20% |
| Weighted Average Cost of Capital (WACC) | 4.19% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.05M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +541.53% in the last 52 weeks. The beta is -0.01, so Climb Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.01 |
| 52-Week Price Change | +541.53% |
| 50-Day Moving Average | 11.80 |
| 200-Day Moving Average | 10.58 |
| Relative Strength Index (RSI) | 58.09 |
| Average Volume (20 Days) | 1,289,614 |
Short Selling Information
The latest short interest is 9.79 million, so 16.66% of the outstanding shares have been sold short.
| Short Interest | 9.79M |
| Short Previous Month | 9.72M |
| Short % of Shares Out | 16.66% |
| Short % of Float | 26.52% |
| Short Ratio (days to cover) | 7.21 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.76M |
| Pretax Income | -59.31M |
| Net Income | -59.31M |
| EBITDA | -66.46M |
| EBIT | -66.76M |
| Earnings Per Share (EPS) | -$0.82 |
Balance Sheet
The company has $205.42 million in cash and $1.07 million in debt, with a net cash position of $226.56 million or $3.86 per share.
| Cash & Cash Equivalents | 205.42M |
| Total Debt | 1.07M |
| Net Cash | 226.56M |
| Net Cash Per Share | $3.86 |
| Equity (Book Value) | 228.05M |
| Book Value Per Share | 3.95 |
| Working Capital | 202.24M |
Cash Flow
In the last 12 months, operating cash flow was -$52.56 million and capital expenditures -$1.08 million, giving a free cash flow of -$53.64 million.
| Operating Cash Flow | -52.56M |
| Capital Expenditures | -1.08M |
| Depreciation & Amortization | 296,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -53.64M |
| FCF Per Share | -$0.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Climb Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.58% |
| Shareholder Yield | -6.58% |
| Earnings Yield | -7.01% |
| FCF Yield | -7.78% |
Analyst Forecast
The average price target for Climb Bio is $28.40, which is 141.91% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.40 |
| Price Target Difference | 141.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |